Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations 2

• 資料種別: 博士論文
• ISSN: 0344-5704
• タイトル: Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations
• 巻次・部編番号: 78 2
• 著者・編者: 溝口, 孝輔
• 著者標目: 溝口, 孝輔
• 出版事項: Springer
• 出版年月日等: 2017-02-01
• 出版年（W3CDTF）: 2017-02-01
• 並列タイトル等: ゲフィチニブの薬物動態パラメーターと無増悪生存期間・有害事象との相関
• タイトル（掲載誌）: Cancer Chemotherapy and Pharmacology
• 授与機関名: Nagasaki University (長崎大学)
• 授与年月日: 2017-02-01
• 授与年月日（W3CDTF）: 2017-02-01
• 報告番号: 甲医歯薬第914号
• 学位: 博士(医学)
• 博論授与番号: 甲医歯薬第914号
• 本文の言語コード: eng
• 件名標目: Chemotherapy; EGFR mutations; Elimination half-life; Gefitinib; Non-small cell lung cancer; Pharmacokinetics
• 対象利用者: 一般
• 一般注記: Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Patients and methods: Plasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib were also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib. Results: The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8. The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h. The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days. A high D8/D2 ratio was significantly correlated with better PFS, though the plasma trough levels on D2 and D8 were not significantly related to PFS. The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events. Pharmacokinetic parameters were not significantly correlated with OS. Conclusions: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. On the other hand, long elimination half-life was related to high-grade adverse events in these patients.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第914号 学位授与年月日:平成29年2月1日; Nagasaki University (長崎大学), 博士(医学) (2017-02-01)
• DOI: info:doi/10.1007/s00280-016-3097-4; https://doi.org/info:doi/10.1007/s00280-016-3097-4
• 国立国会図書館永続的識別子: info:ndljp/pid/10310784; https://dl.ndl.go.jp/pid/10310784
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• 収集根拠: 博士論文（自動収集）
• 受理日（W3CDTF）: 2017-03-02T13:20:07+09:00
• 作成日（W3CDTF）: 2020-12-21
• 記録形式（IMT）: PDF
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: http://hdl.handle.net/10069/37043; https://nagasaki-u.repo.nii.ac.jp/records/3858
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

目次

2021-03-07 再収集